cisplatin,pembrolizumab,enfortumab vedotin,atezolizumab,nivolumab,ipilimumab
astellas,merck,bms,seagen,roche
['muc ,(-much)', 'vedo', 'solid tumor', 'pembro', 'atezo', ' vedo', 'cisplatin', 'key,note,361', ' cis ', 'imvigor130', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ev-302', 'ev-103', 'check,mate,901', 'bladder', ' uc,(-ucsd),(-ucsf),']
breaking down the complex io landscape of #muc #gu23 role of io monotherapy and chemo+io &amp; highlighting questions of:
- benefit of combinations chemo with pd1 vs pdl1?
- benefit of combination of cis vs carbo with io?
- role of ev+io? 
Medical oncologist @GACancerCenter, Augusta University specializing in genitourinary &breast oncology. Editor and TB moderator @themednet.org #patientadvocate